Chemical structure of clarithromycin.
Find information on thousands of medical conditions and prescription drugs.

Clarithromycin

Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections, and, in HIV and AIDS patients to prevent, and to treat, disseminated Mycobacterium avium complex or MAC. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

In addition, it is sometimes used to treat Legionellosis.

Clarithromycin is available under several brandnames, for example Biaxin and Klacid.

History

Abbott Laboratories brought out clarithromycin in 1991.

Available forms

Clarithromycin is commonly administered in tablets (Biaxin®), extended-release tablets (Biaxin XL®), or oral suspension.

Mechanism of action

Clarithromycin prevents bacteria from growing, by interfering with their protein synthesis. Clarithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Clarithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophilae. Besides this bacteriostatic effect, clarithromycin also has bactericidal effect on certain strains such as Haemophilus influenzae, Streptococcus pneumoniae and Neisseria gonorrhoeae.

Pharmacokinetics

Unlike erythromycin, clarithromycin is acid-stable and can therefore be taken orally without being protected from gastric acids. It is readily absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, clarithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of clarithromycin is released. The concentration of clarithromycin in the tissues can be over 10 times higher than in plasma. Highest concentrations were found in liver and lung tissue.

Metabolism

Clarithromycin has a fairly rapid first-pass hepatic metabolism, i.e it is metabolised by the liver. However, this metabolite, 14-hydroxy clarithromycin is almost twice as active as clarithromycin. The half-life of clarithromycin is about 5 hours and 14-hydroxy clarithromycin's about 7 hours. Clarithromycin's and its metabolites' main routes of elimination are urinary and biliary excretion.

Side effects

Most common side-effects are gastrointestinal; diarrhea, nausea, abdominal pain and vomiting. Less common side-effects include headaches, rashes, alteration in senses of smell and taste.

Special Precautions

Allergic reactions can occur with clarithromycin use. People with a history of allergy, asthma, hay fever or hives seem to be more susceptible to these reactions. The reaction can be immediate and severe.

Allergic symptoms include wheezing, hives, itching, swelling, spasms in the throat and breathing tubes, joint and muscle pain, difficulty breathing, fever and skin rashes. Nausea and vomiting are not symptoms of an allergic reaction.

Read more at Wikipedia.org


[List your site here Free!]


Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion
From CHEST, 7/1/02 by Etsuko Tagaya

Study objective: Long-term administration of macrolide antibiotics reduces sputum production in patients with chronic airway diseases, probably by inhibiting airway inflammation. The objective of the present study was to determine the acute effects of a macrolide on airway chloride secretion and sputum production.

Methods: We first investigated the effect of erythromycin treatment on chloride diffusion potential difference (CPD) across tracheal mucosa in vivo. Next, we conducted a double-blind, parallel-group study examining the effect of 7 days of treatment with clarithromycin (400 mg/d), amoxicillin (1,500 mg/d), or cefaclor (750 mg/d) in patients with chronic bronchitis or bronchiectasis without apparent respiratory infection.

Results: IV administration of erythromycin decreased the CPD of rabbit tracheal mucosa in a dose-dependent manner. Treatment of patients with clarithromycin decreased sputum production, whereas amoxicillin and cefaclor treatment had no effect. The percentage of patients whose sputum decreased > 30% from baseline (responders) was 38% in the clarithromycin group, 7% in the amoxicillin group, and 0% in the cefaclor group. During treatment with clarithromycin, the sputum solid composition increased and chloride concentration decreased in responders, but these changes were not observed in nonresponders.

Conclusion: Short-term administration of 14-membered macrolide reduces chronic airway hypersecretion, presumably by inhibiting chloride secretion and the resultant water secretion across the airway mucosa.

Key words: airway secretion; bronchiectasis; chronic bronchitis; macrolide antibiotics

Abbreviations: CPD = chloride diffusion potential difference; K-H = Krebs-Henseleit; mV = millivolt; PD = potential difference; %SC = percentage of solid composition

**********

Macrolide antibiotics are effective in the treatment of acute bronchitis and chronic airway diseases, including chronic bronchitis and diffuse panbronchiolitis. (1,2) The efficacy of macrolide antibiotics may be derived not only from their antimicrobial activities but also from immunomodulatory and anti-inflammatory actions. (3) In addition, we have previously shown that administration of macrolides for 6 weeks reduces sputum production in patients with chronic airway hypersecretion, but the mechanism remain uncertain. Although it is possible that the antisecretory effect of macrolides could be associated with the inhibition of airway epithelial chloride secretion and the resultant reduction in water transport across the airway mucosa toward the lumen, (4) this hypothesis is based on in vitro evidence and thus may not accurately reflect the drug actions in vivo. Therefore, in the present study, we first examined the effect of erythromycin on chloride diffusion potential difference (CPD) across the rabbit tracheal mucosa in vivo. If the macrolide causes a rapid inhibition of chloride secretion in this experiment, then it is expected that short-term administration of the drug might reduce airway secretion. We thus conducted a double-blind study looking at the effect of 7 days of treatment with clarithromycin on sputum production in patients with chronic bronchitis or bronchiectasis.

MATERIALS AND METHODS

Animal Study

Measurement of Potential Difference In Vivo: Measurement of tracheal mucosal potential difference (PD) in vivo has been described in detail previously. (5,6) Briefly, Japanese white rabbits weighing 1.8 to 2.5 kg were anesthetized with intraperitoneal [alpha]-chloralose (50 mg/kg) and urethane (500 mg/kg), and the trachea was exposed. A polyethylene tube was inserted into the trachea 5 mm above the carina, through which the respirator (model SN-480-7; Shinano; Tokyo, Japan) was connected and mechanical ventilation was performed (tidal volume, 10 mL/kg; respiratory rate, 60 breaths/min). The upper tracheal cartilage rings were then incised transaxially, and the surface of membranous portion was exposed (Fig 1).

[FIGURE 1 OMITTED]

The exploring bridge, constructed of a polyethylene tube 2.5 mm in diameter for in vivo measurement of airway epithelial PD, was placed on the surface of the posterior membrane above the carina. Contact with the tracheal mucosal surface was ensured by continuous perfusion (0.3 mL/min) through the bridge with Krebs-Henseleit (K-H) solution of the following composition: 118 mM NaCl, 5.9 mM KCl, 2.5 mM Ca[Cl.sub.2], 1.2 mM MgS[O.sub.4], 1.2 mM Na[H.sub.2]P[O.sub.4], 1.2 mM NaHC[O.sub.3], and 25.5 mM glucose, warmed at 37[degrees]C and adjusted pH to 7.4. The whole area of exposed mucosal surface of the trachea was perfused, and the perfusion reservoir was connected to the calomel electrode via a polyethylene tube (1.5 mm in diameter) filled with 3% agar in saline solution.

The reference bridge, a 21-gauge needle that contained 3% agar in saline solution, was inserted into the subcutaneous space of the right anterior chest wall, which was isoelectric with the adventitial surface of the trachea. Each bridge was connected by a calomel electrode to a high-impedance voltmeter (model CEZ-9100; Nihon Kohden; Tokyo, Japan). The electrical signal was filtered to remove 60-cycle interference, and the PD between the tracheal mucosal surface and subcutaneous space (transmembrane PD) was continuously recorded on a pen recorder (model SR 6335; Graphtec; Tokyo, Japan).

In Japan, clarithromycin has been used much more frequently than erythromycin for the treatment of chronic airway diseases. Although they are both 14-membered macrolides, clarithromycin is difficult to dissolve in K-H solution compared with erythromycin. We thus used erythromycin in the animal study.

Effect of Erythromycin on PD: After equilibration, the tracheal mucosa was continuously perfused with K-H solution containing amiloride ([10.sup.-4] mol/L), a sodium channel blocker. Under this circumstance, the remaining PD (CPD) is an index of epithelial cellular and paracellular paths available for chloride diffusion. (7) After the CPD became stable, erythromycin was administered via mucosal or submucosal routes. For mucosal application, erythromycin at a final concentration of [10.sup.-5] mol/L or [10.sup.-4] mol/L was added to the amiloride-containing superfusing solution. For submucosal application, erythromycin, 10 mg/kg/h, was administered via the jugular vein by a bolus injection. Our preliminary study showed that vehicle alone administered by either route had no effect on CPD.

To determine the dose-response relationship for IV-administered erythromycin, increasing doses (1, 3, 10, and 30 mg/kg/h) were administered, while CPD was continuously recorded. In each instance, the next higher dose was administered 5 min after the CPD response to the preceding dose reached a plateau. Since even high concentrations of erythromycin did not alter the CPD when administered by superfusion, no dose-response curves were generated for this route of administration.

Clinical Study

Patients: Forty-five patients, 38 to 77 years of age, with chronic bronchitis or bronchiectasis who had been continuously expectorating > 20 g of sputum per day for at least 2 weeks prior to the study were recruited after their consent was obtained. All cases of chronic bronchitis conformed to the World Hearth Organization definition of the disease. (8) Bronchiectasis was confirmed by CT of the chest. There was no evidence of current respiratory infection, based on chest radiography and sputum bacteriology.

Study Design: The study was conducted in a double-blind, parallel-group fashion. A doctor not involved in the disease follow-up or data analysis was assigned the task of classifying the patients into three groups matched for clinical diagnosis (Table 1). Patients continued their usual medications, including oral [[beta].sub.2]-adrenergic agonists, oral theophylline, oral mucolytic agents, inhaled corticosteroids, and inhaled anticholinergic agents. In the first group (the clarithromycin group; n = 16), patients received oral clarithromycin, 100 mg bid for 7 days. In the second group (the amoxicillin group; n = 15), patients received oral amoxicillin, 500 mg, tid for 7 days. In the third group (the cefaclor group; n = 14), patients received oral cefaclor, 250 mg tid for 7 days. Patient compliance with the medication schedule was assessed from an individual record supplied by each patient at the end of the trial.

Analysis of Sputum: The patients were given preweighed, covered, plastic cups, and were asked to collect and weigh all sputum expectorated during every 24 h of the trial period at home. At the beginning and after 7 days of the trial, sputum samples collected in the morning (7 AM to 10 AM) were transported to the laboratory. After determination of the wet weight, they were dried in a microwave oven (500 W for 30 min) and reweighed. The percentage of solid composition (%SC) was then calculated from the ratio of wet to dry weight. (9) After centrifugation of sputum, the concentration of chloride in the supernatant was measured by a chloridometer.

Statistical Analysis

All date are expressed as means [+ or -] SEM. Statistical analysis was performed by Student t test or the Kruskal-Walls one-way analysis of variance, and p < 0.05 was considered statistically significant.

RESULTS

Transepithelial PD of Rabbit Tracheal Mucosa In Vivo

The in vivo PD of rabbit tracheal mucosa became stable within 5 min after perfusion with K-H solution, and the baseline PD value was 19.4 [+ or -] 1.7 millivolts (mV) [n = 14], lumen negative. As shown in Figure 2, application of amiloride at [10.sup.-4] mol/L of the superfusing solution reduced the PD to 11.0 [+ or -] 1.2 mV (n = 14); this value is identified as the baseline CPD. Subsequent application of erythromycin at [10.sup.-5] mol/L or [10.sup.-4] mol/L to the superfusate did not significantly alter the CDPD. However, IV administration of erythromycin at 10 mg/kg/h decreased the CDPD from 10.5 [+ or -] 0.6 to 6.8 [+ or -] 0.4 mV (p < 0.001; n = 7) within 2 min, a value that remained stable at least for the following 5 min.

[FIGURE 2 OMITTED]

As demonstrated in Figure 3, IV erythromycin reduced the CPD in a dose-dependent fashion. The maximum decrease in CPD from the baseline value was 5.7 [+ or -] 0.8 mV (p < 0.001; n = 9), and the apparent dose required to produce a half-maximal effect was 2.7 mg/kg/h. Administration of the vehicle alone had no effect.

[FIGURE 3 OMITTED]

Sputum Production in Patients With Chronic Bronchitis or Bronchiectasis

During the trial, no apparent adverse effects were seen in either treatment group. As shown in Figure 4, treatment with clarithromycin for 7 days decreased sputum production from 34 [+ or -] 5 to 25 [+ or -] 5 g/d (p < 0.05; n = 16), whereas amoxicillin and cefaclor had no effect. In the clarithromycin group, 6 of 16 patients (38%) showed the reduction of sputum volume by > 30% of baseline, whereas only 1 of 15 patients (6.7%) in the amoxicillin group and no patients in the cefaclor group did so. We defined the patients whose sputum volume was decreased > 30% of baseline as responders, and the others as nonresponders, and analysis of the sputum was compared between these two groups.

[FIGURE 4 OMITTED]

In responders, administration of clarithromycin for 7 days increased %SC from 2.5 [+ or -] 0.3% to 3.2 [+ or -] 0.3%. In contrast, the values for %SC in nonresponders were higher than those of responders and did not change after the treatment with clarithromycin (Fig 5). The sputum chloride concentrations were higher in responders than in nonresponders before treatment, and administration of clarithromycin decreased chloride concentrations from 191 [+ or -] 20 to 157 [+ or -] 18 mM (p < 0.05; n = 6) in responders, whereas it was without effect in nonresponders (Fig 5).

[FIGURE 5 OMITTED]

DISCUSSION

In our present study, we first looked at the effect of erythromycin on transepithelial PD of rabbit trachea in vivo. Epithelial cells in the central airway absorb Na from and secrete chloride toward the lumen, and the net ion flux through epithelial cellular and paracellular paths generates a transepithelial PD, which concomitantly promotes water movement across the airway mucosa. (10) In this study, the PD determined after addition of amiloride that eliminates the Na component of transport is assumed to reflect most likely chloride secretion. This CPD was rapidly reduced by IV erythromycin in a dose-dependent manner, indicating that this drug inhibits airway epithelial secretion of chloride toward the respiratory lumen. Since inhibition of chloride secretion reduces subsequent movement of water toward the lumen, the observed effect of erythromycin on CPD strongly suggests that it may inhibit water secretion and, hence, decrease the amount of sputum production. However, possible contributions of electrolyte transport processes other than chloride, such as amiloride-insensitive Na, Na-glucose co-transport, and bicarbonate diffusion, cannot be ruled out.

Previous in vitro studies (11,12) showed that airway epithelial chloride secretion was inhibited by macrolide antibiotics but not by a group of penicillin, cephalosporin, aminoglycoside or tetracycline, indicating the effect is specific for macrolides. Additionally, the inhibition of chloride secretion by macrolide can be observed only when the drug is applied to the submucosal side of the epithelium, possibly due to the difference in distribution of the receptor. (12) In agreement with this finding, IV but not mucosal application of erythromycin caused a decrease in CPD in our in vivo experiment. The mechanism by which macrolides inhibit airway epithelial chloride secretion is unknown. Several airway epithelial functions are controlled by the autonomic neural pathway, which plays a role in chloride secretion and the maintenance of epithelial PD in vivo, (13) and it is known that erythromycin inhibits the release of acetylcholine from the airway cholinergic nerve terminals. (14) Therefore, although it is possible that macrolides have a direct inhibitory action on airway epithelial chloride channels, the inhibition of cholinergic neurotransmission could also be involved.

On the basis of the finding in the CPD experiment, we conducted a clinical study and found that short-term treatment with clarithromycin but not amoxicillin or cefaclor caused a significant decrease in the amount of sputum expectorated by patients with chronic bronchitis or bronchiectasis. Furthermore, in responders to clarithromycin, the decrease in sputum production was accompanied by the increase in %SC of the sputum, which is suggestive of less hydration. However, although not significant, the mean calculated values of total solids were decreased (1.03 g/d on day 0, and 0.70 g/d on day 7). This finding is compatible with the previous finding that macrolide inhibits mucus glycoprotein secretion from human isolated airways. (3) Thus, the reduction of sputum volume by clarithromycin may be largely due to its effect on water transport, presumably involving active ion transport processes in the airway epithelium.

There seemed to exist responders and nonresponders in our patients. We found that responders had higher chloride content and lower %SC in their sputum compared with nonresponders, and that these values changed after treatment with clarithromycin along with the decrease in sputum volume. These results suggest that macrolide therapy is effective in patients having "watery" sputum, and that the drug may exert its effect by inhibiting airway epithelial chloride secretion and the concomitant secretion of water toward the lumen. However, actual ion transport properties of airway epithelium in chronic bronchitis and bronchiectasis are unknown, and the mechanism of difference between responders and nonresponders warrants further studies.

ACKNOWLEDGMENT: The authors thank Masayuki Shino and Yoshimi Sugimura for technical assistance.

REFERENCES

(1) Suez D, Szefler SJ. Excessive accumulation of mucus in children with asthma. J Allergy Clin Immunol 1986; 77: 330-334

(2) Willey RF, Gould JC, Grant WB. A comparison of ampicillin, erythromycin and erythromycin with sulphametopyyrazine in the treatment of infective exacerbations of chronic bronchitis. Br J Dis Chest 1978; 72:12-20

(3) Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990; 141:72-78

(4) Tamaoki J, Konno K. Effect of erythromycin on bioelectric properties of tracheal epithelium in culture. Sarcoidosis 1992; 9:645-648

(5) Boucher RC, Bromberg PA, Gatzy JT. Airway transepithelial electric potential in vivo: species and regional differences. J Appl Physiol 1980; 48:169-176

(6) Takemura H, Tamaoki J, Tagaya E, et al. Isoproterenol increases Cl diffusion potential difference of rabbit trachea through nitric oxide generation. J Pharmacol Exp Ther 1995; 274:584-588

(7) Stutts MJ, Knomles MR, Chinet T, et al. Abnormal ion transport in cystic fibrosis airway epithelium. In: Farmer SG, Hay DWP, eds. The airway epithelium: lung biology in health and disease (vol 55). New York, NY: Marcel Dekker, 1990; 301-334

(8) World Health Organization. Epidemiology of chronic non-specific respiratory diseases. Bull World Health Organ 1975; 52:251-259

(9) Rubin BK, Ramirez O, Zayas JG, et al. Collection and analysis of respiratory mucus from subjects without lung disease. Am Rev Respir Dis 1990; 115:989-995

(10) Welsh MJ, Widdicombe JH, Nedel JA. Fluid transport across the canine tracheal epithelium. J Appl Physiol 1980; 49: 905-909

(11) Ikeda K, Wu D, Takasaka T. Inhibition of acetylcholine-evoked Cl currents by 14-membered macrolide antibiotics in isolated acinar cells of the guinea pig nasal gland. Am J Respir Cell Mol Biol 1995; 13:449-454

(12) Tamaoki J, Isono K, Sakai N, et al. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992; 5:234-238

(13) Tamaoki J, Chiyotani A, Tagaya E, et al. Cholinergic control of rabbit tracheal transepithelial potential difference in vivo. Eur Respir J 1996; 9:1632-1636

(14) Tamaoki J, Tagaya E, Sakai A, et al. Effect of macrolide antibiotics on neutrally mediated contraction of human isolated bronchus. J Allergy Clin Immunol 1995; 95:853-859

* From the First Department of Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

This work was supported in part by grant 12770305 from the ministry of Education, Science and Culture, Japan.

Manuscript received August 16, 2001; revision accepted January 7, 2002.

Correspondence to: Atsushi Nagai, MD, First Department of Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-Cho, Shinjuku, Tokyo 162-8666, Japan; e-mail: anagai@chi.twmu.ac.jp

COPYRIGHT 2002 American College of Chest Physicians
COPYRIGHT 2002 Gale Group

Return to Clarithromycin
Home Contact Resources Exchange Links ebay